Pre-Differentiation of KIND1 Human Embryonic Stem Cell Line into Type I Alveolar Epithelial Cells Alleviates Symptoms of Idiopathic Pulmonary Fibrosis in Mice

DOI: https://doi.org/10.1007/s12595-023-00469-2

2023-03-11

Proceedings of the Zoological Society

Abstract:Stem cell therapy uses of the ability of stem cells to differentiate into cells of other lineages, engraft into damaged tissues and promote their regeneration. However, the use of ESCs has been limited due to safety issues, which we have attempted to overcome by differentiating the cells before transplantation. In this study, we have induced the differentiation of KIND1 hESC line using a cocktail of growth factors present in SAGM. These differentiated cells were then transplanted into a bleomycin-induced mouse model of IPF, a degenerative lung disease with no permanent cure, to determine whether they could reduce the symptoms of the disease. We found that KIND1 hESCs, grown in SAGM for 48 h, predominantly differentiated into AQP5 + type-I alveolar epithelial cells, and a small fraction of SP-C + AE-II cells. When transplanted into mice with IPF, these differentiated cells showed a significant alleviation of the disease symptoms, by engrafting into, and promoting regeneration of, the damaged tissue, thereby restoring the gas exchange capacity of the lungs. Thus, pre-differentiating hESCs into a specific lineage before transplantation could provide a safer and more economical therapy for degenerative diseases like IPF.